Aglepristone for Feline Mammary Hyperplasia

Jurka, P. and A. Max (2009). "Treatment of fibroadenomatosis in 14 cats with aglespristone - changes in blood parameters and follow-up." Vet Record 165(22): 657-660.

Mammary hyperplasia (also called fibroadenomatosis or fibroadenomatous hyperplasia) is a benign inflammatory condition commonly seen in young cycling queens. It may also be seen in pregnant queens, and in male or female cats treated with progestins. The hyperplasia can be severe, leading to tissue necrosis, ulceration and infection. The etiology is suspected to be an exaggerated response to natural progesterone or synthetic progestins, but the disease is also rarely reported in sterilized male or female cats with no history of progestin therapy. In spayed queens, ovarian remnant syndrome may be the initiating cause. Many drug therapies have been tried, but the current drug of choice is the progesterone receptor blocker aglepristone (Alizine®, Virbac). Widely available in many countries around the world, it is not available in North America. The drug is also used for pregnancy termination and treatment of cystic endometrial hyperplasia/pyometra complex. The researchers, based in Warsaw, diagnosed 14 female cats with mammary hyperplasia and treated them with aglepristone. The cats were followed up for 12 months after the end of treatment. On average, complete clinical remission of the mammary hyperplasia was achieved 3.9 weeks after initiation of treatment. If the cat had been previously treated with a progestin, a longer treatment period with aglepristone was recommended. After treatment, six queens were bred and four successfully produced at least one litter of kittens. This research confirms the safety and efficacy of aglepristone for treatment of mammary hyperplasia in cats. [SL]
>> Journal Abstract

Related articles:
Gorlinger, S., H. S. Kooistra, et al. (2002). "Treatment of fibroadenomatous hyperplasia in cats with aglepristone." J Vet Intern Med 16(6): 710-3.
>> PubMed Abstract

Nak, D., Y. Nak, et al. (2009). "Follow-up examinations after medical treatment of pyometra in cats with the progesterone-antagonist aglepristone." Journal of Feline Medicine & Surgery 11(6): 499-502.
>> Pubmed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter

Jurka, P. and A. Max (2009). "Treatment of fibroadenomatosis in 14 cats with aglespristone - changes in blood parameters and follow-up." Vet Record 165(22): 657-660.

Mammary hyperplasia (also called fibroadenomatosis or fibroadenomatous hyperplasia) is a benign inflammatory condition commonly seen in young cycling queens. It may also be seen in pregnant queens, and in male or female cats treated with progestins. The hyperplasia can be severe, leading to tissue necrosis, ulceration and infection. The etiology is suspected to be an exaggerated response to natural progesterone or synthetic progestins, but the disease is also rarely reported in sterilized male or female cats with no history of progestin therapy. In spayed queens, ovarian remnant syndrome may be the initiating cause. Many drug therapies have been tried, but the current drug of choice is the progesterone receptor blocker aglepristone (Alizine®, Virbac). Widely available in many countries around the world, it is not available in North America. The drug is also used for pregnancy termination and treatment of cystic endometrial hyperplasia/pyometra complex. The researchers, based in Warsaw, diagnosed 14 female cats with mammary hyperplasia and treated them with aglepristone. The cats were followed up for 12 months after the end of treatment. On average, complete clinical remission of the mammary hyperplasia was achieved 3.9 weeks after initiation of treatment. If the cat had been previously treated with a progestin, a longer treatment period with aglepristone was recommended. After treatment, six queens were bred and four successfully produced at least one litter of kittens. This research confirms the safety and efficacy of aglepristone for treatment of mammary hyperplasia in cats. [SL]
>> Journal Abstract

Related articles:
Gorlinger, S., H. S. Kooistra, et al. (2002). "Treatment of fibroadenomatous hyperplasia in cats with aglepristone." J Vet Intern Med 16(6): 710-3.
>> PubMed Abstract

Nak, D., Y. Nak, et al. (2009). "Follow-up examinations after medical treatment of pyometra in cats with the progesterone-antagonist aglepristone." Journal of Feline Medicine & Surgery 11(6): 499-502.
>> Pubmed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter

Read More

Lysine for Feline Upper Respiratory Tract Disease

Drazenovich, T. L., A. J. Fascetti, et al. (2009). "Effects of dietary lysine supplementation on upper respiratory and ocular disease and detection of infectious organisms in cats within an animal shelter." Am J Vet Res 70(11): 1391-400.

Feline herpesvirus (FHV) is a common cause of respiratory infections in cats housed in shelter situations. Cats latently infected with feline herpesvirus are important sources of the virus for cats that are susceptible to infection. Medications that interfere with latency establishment or reactivation of latent infections would be extremely useful, especially in rescue facilities, where animals are often highly stressed, and have variable vaccination history and immune status. Lysine has shown promise in mediating antiviral effects in cats. These researchers investigated the usefulness of dietary supplementation with lysine for cats in shelters to decrease incidence of infection and detection of FHV shedding. Using 261 adult cats, basal diets (control group) and diets supplemented with lysine (treated group) were fed for four weeks. Unexpectedly, they found that treated cats were actually more likely to manifest severe disease than untreated controls at certain time points in the study (week 4). In addition, FHV was detected more commonly in treated cats (found in week 2 only). A confounding factor was that cats in both groups were also allowed access to commercial diets when hospitalized for illness in addition to the control and test diets. The researchers concluded that continuous dietary supplementation with lysine did not successfully control respiratory disease in a shelter situation, and is not an optimal use of funds in rescue facilities. Bolus treatment of cats with lysine may provide better plasma lysine levels than continuous dietary supplementation, and may provide more beneficial effects.
>> PubMed Abstract

Related articles:
Maggs, D. J., J. E. Sykes, et al. (2007). "Effects of dietary lysine supplementation in cats with enzootic upper respiratory disease." J Feline Med Surg 9(2): 97-108.
>> PubMed Abstract

Rees, T. M. and J. L. Lubinski (2008). "Oral supplementation with L-lysine did not prevent upper respiratory infection in a shelter population of cats." J Feline Med Surg 10(5): 510-3.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter

Drazenovich, T. L., A. J. Fascetti, et al. (2009). "Effects of dietary lysine supplementation on upper respiratory and ocular disease and detection of infectious organisms in cats within an animal shelter." Am J Vet Res 70(11): 1391-400.

Feline herpesvirus (FHV) is a common cause of respiratory infections in cats housed in shelter situations. Cats latently infected with feline herpesvirus are important sources of the virus for cats that are susceptible to infection. Medications that interfere with latency establishment or reactivation of latent infections would be extremely useful, especially in rescue facilities, where animals are often highly stressed, and have variable vaccination history and immune status. Lysine has shown promise in mediating antiviral effects in cats. These researchers investigated the usefulness of dietary supplementation with lysine for cats in shelters to decrease incidence of infection and detection of FHV shedding. Using 261 adult cats, basal diets (control group) and diets supplemented with lysine (treated group) were fed for four weeks. Unexpectedly, they found that treated cats were actually more likely to manifest severe disease than untreated controls at certain time points in the study (week 4). In addition, FHV was detected more commonly in treated cats (found in week 2 only). A confounding factor was that cats in both groups were also allowed access to commercial diets when hospitalized for illness in addition to the control and test diets. The researchers concluded that continuous dietary supplementation with lysine did not successfully control respiratory disease in a shelter situation, and is not an optimal use of funds in rescue facilities. Bolus treatment of cats with lysine may provide better plasma lysine levels than continuous dietary supplementation, and may provide more beneficial effects.
>> PubMed Abstract

Related articles:
Maggs, D. J., J. E. Sykes, et al. (2007). "Effects of dietary lysine supplementation in cats with enzootic upper respiratory disease." J Feline Med Surg 9(2): 97-108.
>> PubMed Abstract

Rees, T. M. and J. L. Lubinski (2008). "Oral supplementation with L-lysine did not prevent upper respiratory infection in a shelter population of cats." J Feline Med Surg 10(5): 510-3.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter

Read More